Monopar (NASDAQ: MNPR) director to sell 6,284 shares

Rhea-AI Filing Summary

Monopar Therapeutics (MNPR) has a notice from director Raymond William Anderson to sell shares of its common stock under Rule 144. The notice covers 6,284 shares of common stock, to be received and sold upon the exercise of stock options over a three‑month period, with trades listed for NASDAQ and handled through Morgan Stanley Smith Barney LLC. The securities will be paid for in cash, and the stated date associated with the proposed sale is 08/25/2026.

Key Figures

Shares of common stock to be sold: 6,284 shares Date associated with securities information: 08/25/2026 Date of Notice: 05/26/2026

3 metrics

Shares of common stock to be sold 6,284 shares Common stock covered by Raymond Anderson’s Rule 144 notice

Date associated with securities information 08/25/2026 Date listed with 6,284 shares of common stock and NASDAQ

Date of Notice 05/26/2026 Date on which the Form 144 notice was signed and dated

Key Terms

Rule 144, Form 144, exercise of stock options, securities to be sold

4 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Form 144 regulatory

"144: Filer Information 144: Issuer Information"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

exercise of stock options financial

"Common | 08/25/2026 | Exercise of Stock Options | Issuer"

securities to be sold financial

"The securities to be sold were and will be received upon the exercise"

FAQ

What does the Form 144 filing mean for Monopar Therapeutics (MNPR)?

The Form 144 indicates that director Raymond William Anderson has given notice of his intent to sell 6,284 shares of Monopar Therapeutics common stock, which will be obtained through the exercise of stock options and sold for cash on NASDAQ.

How many MNPR shares are covered by Raymond Anderson’s Form 144?

The notice covers 6,284 shares of Monopar Therapeutics common stock. The filing states these securities were and will be received upon the exercise of stock options over the next three months before sale.

How will the MNPR shares in this Form 144 be acquired and sold?

The filing states the shares "were and will be received upon the exercise of stock options" and that the securities to be sold will be paid for in cash, with transactions associated with NASDAQ through Morgan Stanley Smith Barney LLC.

Who is selling Monopar Therapeutics (MNPR) shares under this Form 144?

The notice is filed for Raymond William Anderson, identified as a director of Monopar Therapeutics. The form covers planned sales of his common stock obtained via stock option exercises.

What is the key date mentioned in the Monopar Therapeutics (MNPR) Form 144?

The securities information section lists the date 08/25/2026 in connection with the 6,284 shares of common stock and NASDAQ, and the Form 144 notice itself is dated 05/26/2026.

Which broker is involved in the planned MNPR share sale under Form 144?

The common stock to be sold is associated with Morgan Stanley Smith Barney LLC Executive Financial Services, listed with an address at 1 New York Plaza, in the securities information section of the Form 144.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/25/2026 - 04:45 PM Accepted by SEC EDGAR 08/25/2026 - 04:44 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001362489
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	MONOPAR THERAPEUTICS INC.
SEC File Number	001-39070
Address of Issuer	1000 Skokie Blvd., Suite 350 Wilmette ILLINOIS 60091
Phone	847-388-0349
Name of Person for Whose Account the Securities are To Be Sold	RAYMOND WILLIAM ANDERSON
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	6284	699786.24	6712172	08/25/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/25/2026	Exercise of Stock Options	Issuer			6284	08/25/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks	The securities to be sold were and will be received upon the exercise of stock options over the next three months. The dates of acquisition and payment were and will be the dates of exercise/sale.
Date of Notice	08/25/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	05/26/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Raymond William Anderson
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)